Seegene Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jong-Yoon Chun

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	26.5%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Aug 10

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

Mar 07

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

May 06

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Mar 15

Declining Stock and Solid Fundamentals: Is The Market Wrong About Seegene, Inc. (KOSDAQ:096530)?

Dec 23

Can You Imagine How Elated Seegene's (KOSDAQ:096530) Shareholders Feel About Its 656% Share Price Gain?

Dec 08

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Nov 24

CEO

Jong-Yoon Chun (67 yo)

no data

Tenure

Dr. Jong-Yoon Chun founded Seegene, Inc. in 2000 and serves as its Chief Executive Officer and Chief Technology Officer. Dr. Chun serves as Director at Seegene, Inc.

Seegene Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Seegene, Inc.(KOSDAQ:A096530) dropped from FTSE All-World Index (USD)

Upcoming dividend of ₩200 per share

Investor sentiment deteriorates as stock falls 16%

Seegene, Inc. Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration

New minor risk - Share price stability

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share

Now 20% overvalued

Upcoming dividend of ₩200 per share

Full year 2023 earnings: EPS and revenues exceed analyst expectations

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

New minor risk - Share price stability

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share at 3.5% yield

Price target decreased by 8.8% to ₩25,000

New minor risk - Share price stability

Upcoming dividend of ₩200 per share at 3.7% yield

Consensus EPS estimates fall from profit to ₩18.00 loss

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 30,000 million worth of its shares.

Upcoming dividend of ₩200 per share at 3.7% yield

Upcoming dividend of ₩200 per share at 3.1% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 21%

Upcoming dividend of ₩400 per share

Investor sentiment deteriorated over the past week

Price target decreased to ₩38,667

Less than half of directors are independent

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Upcoming dividend of ₩200 per share

Consensus revenue estimates fall by 24%

Now 20% undervalued

Investor sentiment improved over the past week

Seegene, Inc. to Pave Way for PCR Testing At Local Clinics with EU-Approved Multiplex Test and Fully Automated PCR Solution

Seegene Inc. Develops PCR Test to Detect Monkeypox Virus

Upcoming dividend of ₩400 per share

Now 24% undervalued after recent price drop

Price target decreased to ₩71,500

Seegene, Inc. Unveils World's First Commercialized '3 Ct' PCR Assay

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Seegene's Allplex™ RV Master Assay Receives Australian TGA Approval

Full year 2021 earnings: EPS and revenues miss analyst expectations

Seegene Inc. Unveils New Assay Optimized for On-Site Testing in 'Living with Covid-19' Era

Consensus revenue estimates increase by 13%

Consensus revenue estimates increase by 10%

Investor sentiment improved over the past week

Seegene Inc. to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

Seegene Inc. Announces Allplex Sars Cov-2 FluA/FluB/RSV Assay Approved Under Health Canada's Interim Order

Seegene Inc. Unveils Another Series of Diagnostic Test that Detects the Ever-Changing COVID-19 Variant Landscape

Seegene's High Multiplex Pcr Assay Capable of Detecting New Omicron Variant

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Seegene Inc. Unveils Fully Automated Molecular Testing System At the 2021 AACC

Price target decreased to ₩89,000

Consensus EPS estimates increase to ₩9,305

Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus

Seegene Inc. Introduces its New Deployable Container Laboratory "Mobile Station", at the Medlab Middle East 2021

Investor sentiment improved over the past week

Price target decreased to ₩116,750

Seegene, Inc. Introduces an Exclusive Diagnostic System for Diagnosing Covid-19 Variants

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS ₩19,324 (vs ₩1,026 in FY 2019)

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Seegene Announces Submission to U.S. FDA for Emergency Use Authorization of Its AllplexTM SARS-CoV-2/FluA/FluB/RSV Assay

Price target lowered to ₩291,800

Does Seegene (KOSDAQ:096530) Have A Healthy Balance Sheet?